Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer.

ABSTRACT: Neoadjuvant therapies, primarily chemotherapy and chemoradiotherapy, are able to improve the overall survival (OS) in patients with locally advanced resectable esophageal cancer (EC) based on the results of several randomized clinical trials. The advantage of neoadjuvant therapy is chiefly attributed to the decreased risk of local-regional recurrence and distant metastasis. Thus, it has been recommended as standard treatment for patients with resectable EC. However, several fundamental problems remain. First, the combination of neoadjuvant chemotherapy (nCT), neoadjuvant chemoradiotherapy (nCRT), and surgery for EC patients with different histological types remain controversial. Furthermore, to reduce the toxicity of preoperative chemotherapy and the risk of complications caused by preoper

SUBMITTER: Hou S 

PROVIDER: S-EPMC8533976 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature